Jentashapir Journal of Health Research

Published by: Kowsar

Review of Warfarin; A Cytochrome P450 Metabolizing Drug, in Clinical Practice

Zahra Tolou-Ghamari 1 , * and Hamid Mazdak 2
Authors Information
1 Isfahan Urology and Kidney Transplantation Research Center, Alzahra Research Centers, Isfahan University of Medical Sciences, Isfahan, IR Iran
2 Department of Urology, Alzahra Hospital, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Jentashapir Journal of Health Research: June 01, 2016, 7 (3); e32641
  • Published Online: April 9, 2016
  • Article Type: Review Article
  • Received: August 24, 2015
  • Accepted: September 29, 2015
  • DOI: 10.17795/jjhr-32641

To Cite: Tolou-Ghamari Z, Mazdak H. Review of Warfarin; A Cytochrome P450 Metabolizing Drug, in Clinical Practice, Jentashapir J Health Res. 2016 ; 7(3):e32641. doi: 10.17795/jjhr-32641.

Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet. 1986; 11(6): 483-504[DOI][PubMed]
  • 2. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165(10): 1095-106[DOI][PubMed]
  • 3. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl): 160S-98S[DOI][PubMed]
  • 4. Lam MP, Cheung BM. The pharmacogenetics of the response to warfarin in Chinese. Br J Clin Pharmacol. 2012; 73(3): 340-7[DOI][PubMed]
  • 5. Sharabiani A, Bress A, Douzali E, Darabi H. Revisiting Warfarin Dosing Using Machine Learning Techniques. Comput Math Methods Med. 2015; 2015: 560108[DOI][PubMed]
  • 6. Ogunsua AA, Touray S, Lui JK, Ip T, Escobar JV, Gore J. Body mass index predicts major bleeding risks in patients on warfarin. J Thromb Thrombolysis. 2015; 40(4): 494-8[DOI][PubMed]
  • 7. Leys D, Balucani C, Cordonnier C. Antiplatelet drugs for ischemic stroke prevention. Cerebrovasc Dis. 2009; 27 Suppl 1: 120-5[DOI][PubMed]
  • 8. Schullo-Feulner AM, Stoecker Z, Brown GA, Schneider J, Jones TA, Burnett B. Warfarin dosing after bariatric surgery: a retrospective study of 10 patients previously stable on chronic warfarin therapy. Clin Obes. 2014; 4(2): 108-15[DOI][PubMed]
  • 9. Wagner J, Abdel-Rahman SM. Oseltamivir-warfarin interaction in hypoplastic left heart syndrome: case report and review. Pediatrics. 2015; 135(5)-6[DOI][PubMed]
  • 10. King AE, Strnad K. Probable Interaction Between Warfarin and Banana Flakes Supplement. Nutr Clin Pract. 2016; 31(1): 125-31[DOI][PubMed]
  • 11. Jung HS, Jeon I, Kim SW. Spontaneous Spinal Subdural Hematoma with Simultaneous Cranial Subarachnoid Hemorrhage. J Korean Neurosurg Soc. 2015; 57(5): 371-5[DOI][PubMed]
  • 12. Takizawa S, Tanaka F, Nishiyama K, Hasegawa Y, Nagata E, Mizuma A, et al. Protocol for cerebral microbleeds during the non–vitamin k antagonist oral anticoagulants or warfarin therapy in stroke patients with nonvalvular atrial fibrillation (cmb-now) study: Multisite pilot trial. J Stroke Cerebrovasc Dis. 2015; 24(9): 2143-8
  • 13. Barton CA, Johnson NB, Case J, Warden B, Hughes D, Zimmerman J, et al. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa. Am J Emerg Med. 2015; 33(11): 1562-6[DOI][PubMed]
  • 14. Yuan SM. Warfarin use and dose adjustment in a patient with mitral valve replacement. Pak J Pharm Sci. 2015; 28(4): 1351-5[PubMed]
  • 15. Rubboli A, Becattini C, Verheugt FW. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol. 2011; 3(11): 351-8[DOI][PubMed]
  • 16. Hamberg AK, Hellman J, Dahlberg J, Jonsson EN, Wadelius M. A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children. BMC Med Inform Decis Mak. 2015; 15: 7[DOI][PubMed]
  • 17. Quick JA, Meyer JM, Coughenour JP, Barnes SL. Less Is More: Low-dose Prothrombin Complex Concentrate Effective in Acute Care Surgery Patients. Am Surg. 2015; 81(6): 646-50[PubMed]
  • 18. Stewart A, Ganguli A, FitzGerald R, Pirmohamed M. Variation in warfarin prescribing and dosing in the UK: a national survey of anticoagulation clinics. J Clin Pharm Ther. 2015; 40(4): 466-71[DOI][PubMed]
  • 19. Simon J, Hawes E, Deyo Z, Bryant Shilliday B. Evaluation of prescribing and patient use of target-specific oral anticoagulants in the outpatient setting. J Clin Pharm Ther. 2015; [DOI][PubMed]
  • 20. Kasner SE, Wang L, French B, Messe SR, Horenstein R, Mohler E3, et al. The Impact of Inpatient Versus Outpatient Initiation on Early Warfarin Dosing. Am J Cardiovasc Drugs. 2015; 15(4): 267-74[DOI][PubMed]
  • 21. Limdi NA, Brown TM, Yan Q, Thigpen JL, Shendre A, Liu N, et al. Race influences warfarin dose changes associated with genetic factors. Blood. 2015; 126(4): 539-45[DOI][PubMed]
  • 22. Supe S, Poljakovic Z, Bozina T, Ljevak J, Šarinić VM, Bozina N. Clinical application of genotype-guided dosing of warfarin in patients with acute stroke. Arch med res. 2015; 46(4): 265-73
  • 23. Li X, Liu R, Luo ZY, Yan H, Huang WH, Yin JY, et al. Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients. Pharmacogenomics. 2015; 16(6): 583-90[DOI][PubMed]
  • 24. Tang HL, Shi WL, Li XG, Zhang T, Zhai SD, Xie HG. Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials. Pharmacogenomics J. 2015; 15(6): 496-504[DOI][PubMed]
  • 25. Militaru FC, Vesa SC, Pop TR, Buzoianu AD. Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life. 2015; 8(2): 171-5[PubMed]
  • 26. Dahal K, Sharma S, Fung E, Lee J, Moore JH, Unterborn JN, et al. Meta-analysis of randomized controlled trials of genotype-guided vs standard dosing of warfarin. Chest J. 2015; 148(3): 701-10
  • 27. Weiss D, Knight R, Zhou S, Palmisano M, Chen N. Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting. Clin Drug Investig. 2015; 35(7): 455-61[DOI][PubMed]
  • 28. Lane MA, Zeringue A, McDonald JR. Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. Am J Med. 2014; 127(7): 657-663 e2[DOI][PubMed]
  • 29. Kudo T, Endo Y, Taguchi R, Yatsu M, Ito K. Metronidazole reduces the expression of cytochrome P450 enzymes in HepaRG cells and cryopreserved human hepatocytes. Xenobiotica. 2015; 45(5): 413-9[DOI][PubMed]
  • 30. Howard-Thompson A, Hurdle AC, Arnold LB, Finch CK, Sands C, Self TH. Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. Am J Geriatr Pharmacother. 2008; 6(1): 33-6[DOI][PubMed]
  • 31. Tolou Ghamari Z, Mehavari Habibabadi J, Palizban AA. Evidence-based pharmacotherapy of epilepsy. Arch Neurosci. 2014; 2(2)[DOI]
  • 32. Tolou-Ghamari Z. Antiepileptic drugs (AEDs) polypharmacy could lead to buried pharmacokinetic interactions due to CYP450. Drug Metab Lett. 2012; 6(3): 207-12[PubMed]
  • 33. Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. J Res Med Sci. 2013; 18-5[PubMed]
  • 34. Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. Antiepileptic drugs: a consideration of clinical and biochemical outcome in patients with epilepsy. Int J Prev Med. 2013; 4-7[PubMed]
  • 35. Tolou-Ghamari Z, Najafi MR, Habibabadi JM, Zare M. Preliminarily Analysis of Carbamazepine (CBZ) C0 in Patients Visited Isfahan Epileptic Clinics. Int J Prev Med. 2013; 4-6[PubMed]
  • 36. Kashipazha D, Nejad SEM, Sadr F, Tarahomi S, Sadr S. Comparison of Levetiracetam With Sodium Valproate in Controlling Seizure in Patients Suffering From Juvenile Myoclonic Epilepsy. Jentashapir Journal of Health Research. 2014; 5(4)
  • 37. Lin G, Yi L, Zhang K, Sun Y, Wang L, Zhang R, et al. Improvements in CYP2C9 Genotyping Accuracy Are Needed: A Report of the First Proficiency Testing for Warfarin-related CYP2C9 and VKORC1 Genotyping in China. J Cardiovasc Pharmacol. 2015; 66(2): 129-34[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments